{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:45Z","timestamp":1792872825959,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease with an unknown etiology. Recently, it has been elucidated that dysregulated histone deacetylase (HDAC) activity is related to the pathogenesis of inflammatory and autoimmune diseases. Broad-spectrum HDAC inhibitors are effective for the treatment of allergy, cancer, and autoimmune diseases, but they have several adverse side effects. Thus, the purpose of this study was to evaluate the effects of a novel HDAC 6-specific inhibitor, CKD-506, in a murine SLE model. CKD-506 significantly improved survival rate and significantly decreased the incidence of severe proteinuria, blood urea nitrogen, kidney inflammation, and glomerular infiltration of IgG and C3. In addition, CKD 506 reduced the proportions of CD138<jats:sup>+<\/jats:sup>plasma cells, CD4<jats:sup>\u2212<\/jats:sup>CD8<jats:sup>\u2212<\/jats:sup>T cells, and CD25<jats:sup>+<\/jats:sup>cells and the Th1\/Th2 ratio in the spleen. CKD-506 significantly reduced inflammatory cytokines such as IL-10, IL-15, IL-17, TNF-\u03b1, and IFN-inducible protein (IP-10) and significantly increased TGF-\u03b2 in serum. CKD-506 also significantly reduced IFN-\u03b3, IL-1\u03b2, IL-4, IL-6, IP-10, MCP-1, and CCL4 levels in kidney. CKD-506 decreased the production of various pro-inflammatory cytokines and chemokines in the serum and kidneys, resulting in inhibition of cell migration and suppression of lupus nephritis without adverse effects.<\/jats:p>","DOI":"10.1038\/s41598-018-35602-1","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T11:26:19Z","timestamp":1542626779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus"],"prefix":"10.1038","volume":"8","author":[{"given":"Eun Wha","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Woo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"35602_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMra071297","volume":"358","author":"A Rahman","year":"2008","unstructured":"Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929\u2013939 (2008).","journal-title":"N. Engl. J. Med."},{"key":"35602_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani, S., Meara, A. & Rovin, B. H. Update on Lupus Nephritis. Clin. J. Am. Soc. Nephrol. 12, 825\u2013835 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"35602_CR3","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","volume":"93","author":"Y Wang","year":"1996","unstructured":"Wang, Y. et al. Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93, 8563\u20138568 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"35602_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","volume":"127","author":"C Yildirim-Toruner","year":"2011","unstructured":"Yildirim-Toruner, C. & Diamond, B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy. Clin. Immunol. 127, 303\u2013312 (2011).","journal-title":"J. Allergy. Clin. Immunol."},{"key":"35602_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep38237","volume":"6","author":"EW Choi","year":"2016","unstructured":"Choi, E. W., Lee, M., Song, J. W., Shin, I. S. & Kim, S. J. Mesenchymal stem cell transplantation can restore lupus disease-associated miRNA expression and Th1\/Th2 ratios in a murine model of SLE. Sci. Rep. 6, 38237, https:\/\/doi.org\/10.1038\/srep38237 (2016).","journal-title":"Sci. Rep."},{"key":"35602_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI16153","volume":"111","author":"N Mishra","year":"2003","unstructured":"Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. & Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse. J. Clin. Invest. 111, 539\u2013552 (2003).","journal-title":"J. Clin. Invest."},{"key":"35602_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2119\/molmed.2011.00021","volume":"17","author":"DP Christensen","year":"2011","unstructured":"Christensen, D. P. et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 17, 378\u2013390 (2011).","journal-title":"Mol. Med."},{"key":"35602_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2119\/molmed.2011.00069","volume":"17","author":"R Glauben","year":"2011","unstructured":"Glauben, R. & Siegmund, B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol. Med. 17, 426\u2013433 (2011).","journal-title":"Mol. Med."},{"key":"35602_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2119\/molmed.2010.00152","volume":"17","author":"EC Lewis","year":"2011","unstructured":"Lewis, E. C. et al. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet \u03b2 cells in vivo and in vitro. Mol. Med. 17, 369\u2013377 (2011).","journal-title":"Mol. Med."},{"key":"35602_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1042\/BST20130053","volume":"41","author":"S Hawtree","year":"2013","unstructured":"Hawtree, S., Muthana, M. & Wilson, A. G. The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Biochem. Soc. Trans. 41, 783\u2013788 (2013).","journal-title":"Biochem. Soc. Trans."},{"key":"35602_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30\u201339 (2014).","journal-title":"J. Clin. Invest."},{"key":"35602_CR12","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I. & Piekarz, R. L. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals (Basel) 3, 2751\u20132767 (2010).","journal-title":"Pharmaceuticals (Basel)"},{"key":"35602_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jaci.2014.10.002","volume":"135","author":"G Tsuji","year":"2015","unstructured":"Tsuji, G., Okiyama, N., Villarroel, V. A. & Katz, S. I. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J. Allergy Clin. Immunol. 135, 1228\u20131239 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"35602_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21767\/2472-1158.100015","volume":"2","author":"C Zwergel","year":"2016","unstructured":"Zwergel, C., Stazi, G., Valente, S. & Mai, A. Various Epigenetic-Related Diseases. J. Clin. Epigenet. 2, 1, https:\/\/doi.org\/10.21767\/2472-1158.100015 (2016).","journal-title":"J. Clin. Epigenet."},{"key":"35602_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1074-7613(04)00078-0","volume":"20","author":"JM Serrador","year":"2004","unstructured":"Serrador, J. M. et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 20, 417\u2013428 (2004).","journal-title":"Immunity"},{"key":"35602_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2016.05.014","volume":"97","author":"GS Youn","year":"2016","unstructured":"Youn, G. S., Lee, K. W., Choi, S. Y. & Park, J. Overexpression of HDAC6 induces pro-inflammatory responses by regulating ROS-MAPK-NF-\u03baB\/AP-1 signaling pathways in macrophages. Free Radic. Biol. Med. 97, 14\u201323 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"35602_CR17","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1128\/MCB.01154-06","volume":"28","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 28, 1688\u20131701 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"35602_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4161\/cc.7.1.5186","volume":"7","author":"P Matthias","year":"2008","unstructured":"Matthias, P., Yoshida, M. & Khochbin, S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 7, 7\u201310 (2008).","journal-title":"Cell Cycle"},{"key":"35602_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4479","volume":"5","author":"B Wang","year":"2014","unstructured":"Wang, B. et al. Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nat. Commun. 5, 3479 (2014).","journal-title":"Nat. Commun."},{"key":"35602_CR20","doi-asserted-by":"publisher","first-page":"e110718","DOI":"10.1371\/journal.pone.0110718","volume":"9","author":"B Yan","year":"2014","unstructured":"Yan, B. et al. HDAC6 deacetylase activity is critical for lipopolysaccharide-induced activation of macrophages. Plos One 9, e110718 (2014).","journal-title":"Plos One"},{"key":"35602_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/TA.0000000000000510","volume":"78","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model. J. Trauma Acute Care Surg. 78, 378\u2013385 (2015).","journal-title":"J. Trauma Acute Care Surg."},{"key":"35602_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/1756-185X.12501","volume":"18","author":"J Lee","year":"2015","unstructured":"Lee, J. et al. A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model. Int. J. Rheum. Dis. 18, 514\u2013523 (2015).","journal-title":"Int. J. Rheum. Dis."},{"key":"35602_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clim.2015.11.007","volume":"162","author":"NL Regna","year":"2016","unstructured":"Regna, N. L. et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB\/W mice. Clin. Immunol. 162, 58\u201373 (2016).","journal-title":"Clin. Immunol."},{"key":"35602_CR24","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0430973100","volume":"100","author":"SJ Haggarty","year":"2003","unstructured":"Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100, 4389\u20134394 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"35602_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/toxsci\/kfl068","volume":"93","author":"AJ Olaharski","year":"2006","unstructured":"Olaharski, A. J. et al. The histone deacetylase inhibitor trichostatin a has genotoxic effects in human lymphoblasts in vitro. Toxicol. Sci. 93, 341\u2013347 (2006).","journal-title":"Toxicol. Sci."},{"key":"35602_CR26","doi-asserted-by":"publisher","first-page":"10842","DOI":"10.1021\/ja102758v","volume":"132","author":"KV Butler","year":"2010","unstructured":"Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842\u201310846 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"35602_CR27","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","volume":"119","author":"L Santo","year":"2012","unstructured":"Santo, L. et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579\u20132589 (2012).","journal-title":"Blood"},{"key":"35602_CR28","unstructured":"Raje, N. et al. Ricolinostat (ACY-1215) the first selective HDAC6 inhibitor in combination with pomalidomide and dexamethasone in patients with relapsed & refractory multiple myeloma: Phase 1B & Phase 2 results. EHA Learning Center 100529 (2015)."},{"key":"35602_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","volume":"17","author":"AJ Yee","year":"2016","unstructured":"Yee, A. J. et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 17, 1569\u20131578 (2016).","journal-title":"Lancet Oncol."},{"key":"35602_CR30","doi-asserted-by":"publisher","first-page":"e58140","DOI":"10.1371\/journal.pone.0058140","volume":"8","author":"S Lacotte","year":"2013","unstructured":"Lacotte, S. et al. Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. Plos One 8, e58140, https:\/\/doi.org\/10.1371\/journal.pone.0058140 (2013).","journal-title":"Plos One"},{"key":"35602_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/08916934.2010.545846","volume":"44","author":"K Minowa.","year":"2011","unstructured":"Minowa., K. et al. Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus. Autoimmunity 44, 357\u2013362 (2011).","journal-title":"Autoimmunity"},{"key":"35602_CR32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4049\/jimmunol.143.1.103","volume":"143","author":"S Shivakumar","year":"1989","unstructured":"Shivakumar, S., Tsokos, G. C. & Datta, S. K. T cell receptor alpha\/beta expressing double-negative (CD4\u2212\/CD8\u2212) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143, 103\u2013112 (1989).","journal-title":"J. Immunol."},{"key":"35602_CR33","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","volume":"181","author":"JC Crisp\u00edn","year":"2008","unstructured":"Crisp\u00edn, J. C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181, 8761\u20138766 (2008).","journal-title":"J. Immunol."},{"key":"35602_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","volume":"16","author":"A Zickert","year":"2015","unstructured":"Zickert, A. et al. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. B. M. C. Immunol. 16, 7, https:\/\/doi.org\/10.1186\/s12865-015-0070-7 (2015).","journal-title":"B. M. C. Immunol."},{"key":"35602_CR35","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","volume":"89","author":"F Rousset","year":"1992","unstructured":"Rousset, F. et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89, 1890\u20131893 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"35602_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/rheumatology\/40.8.876","volume":"40","author":"M Aringer","year":"2001","unstructured":"Aringer, M. et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 40, 876\u2013881 (2001).","journal-title":"Rheumatology (Oxford)"},{"key":"35602_CR37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4049\/jimmunol.154.2.483","volume":"154","author":"RJ Armitage","year":"1995","unstructured":"Armitage, R. J., Macduff, B. M., Eisenman, J., Paxton, R. & Grabstein, K. H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 154, 483\u2013490 (1995).","journal-title":"J. Immunol."},{"key":"35602_CR38","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO;2-J","volume":"44","author":"M Aringer","year":"2001","unstructured":"Aringer, M., Steiner, G., Graninger, W. & Smolen, J. Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. Arthritis Rheum. 44, 1721\u20131722 (2001).","journal-title":"Arthritis Rheum."},{"key":"35602_CR39","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","volume":"35","author":"A Studnicka-Benke","year":"1996","unstructured":"Studnicka-Benke, A., Steiner, G., Petera, P. & Smolen, J. S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol. 35, 1067\u20131074 (1996).","journal-title":"Br. J. Rheumatol."},{"key":"35602_CR40","first-page":"1","volume":"134","author":"MCM Vissers","year":"1989","unstructured":"Vissers, M. C. M., Fantone, J. C., Wiggins, R. & Kunkel, S. L. Glomerular basement membrane-containing immune complexes stimulate tumor necrosis factor and interleukin-1 production by human monocytes. Am. J. Pathol. 134, 1\u20136 (1989).","journal-title":"Am. J. Pathol."},{"key":"35602_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.1780390103","volume":"39","author":"HM Belmont","year":"1996","unstructured":"Belmont, H. M., Abramson, S. B. & Lie, J. T. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum. 39, 9\u201322 (1996).","journal-title":"Arthritis Rheum."},{"key":"35602_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1191\/096120300678828703","volume":"9","author":"CK Wong","year":"2000","unstructured":"Wong, C. K., Ho, C. Y., Li, E. K. & Lam, C. W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9, 589\u2013593 (2000).","journal-title":"Lupus"},{"key":"35602_CR43","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/jir.2011.0029","volume":"31","author":"SA Apostolidis","year":"2011","unstructured":"Apostolidis, S. A., Lieberman, L. A., Kis-Toth, K., Crisp\u00edn, J. C. & Tsokos, G. C. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interferon Cytokine Res. 31, 769\u2013779 (2011).","journal-title":"J. Interferon Cytokine Res."},{"key":"35602_CR44","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.4049\/jimmunol.161.11.6383","volume":"161","author":"P Schwarzenberger","year":"1998","unstructured":"Schwarzenberger, P. et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J. Immunol. 161, 6383\u20136389 (1998).","journal-title":"J. Immunol."},{"key":"35602_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","volume":"22","author":"JD Fontenot","year":"2005","unstructured":"Fontenot, J. D. et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329\u2013341 (2005).","journal-title":"Immunity"},{"key":"35602_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235\u2013238 (2006).","journal-title":"Nature"},{"key":"35602_CR47","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24499","volume":"60","author":"J Yang","year":"2009","unstructured":"Yang, J. et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 60, 1472\u20131483 (2009).","journal-title":"Arthritis Rheum."},{"key":"35602_CR48","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1128\/MCB.05155-11","volume":"31","author":"EF de Zoeten","year":"2011","unstructured":"de Zoeten, E. F. et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol. Cell Biol. 31, 2066\u20132078 (2011).","journal-title":"Mol. Cell Biol."},{"key":"35602_CR49","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2002873","volume":"5","author":"UH Beier","year":"2012","unstructured":"Beier, U. H. et al. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci. Signal. 5, ra45, https:\/\/doi.org\/10.1126\/scisignal.2002873 (2012).","journal-title":"Sci. Signal."},{"key":"35602_CR50","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L","volume":"42","author":"M Akahoshi","year":"1999","unstructured":"Akahoshi, M. et al. Th1\/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 42, 1644\u20131648 (1999).","journal-title":"Arthritis Rheum."},{"key":"35602_CR51","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","volume":"168","author":"JH Dufour","year":"2002","unstructured":"Dufour, J. H. et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168, 3195\u20133204 (2002).","journal-title":"J. Immunol."},{"key":"35602_CR52","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1006\/cyto.2000.0757","volume":"12","author":"S Narumi","year":"2000","unstructured":"Narumi, S., Takeuchi, T., Kobayashi, Y. & Konishi, K. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine 12, 1561\u20131565 (2000).","journal-title":"Cytokine"},{"key":"35602_CR53","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/ard.2010.144485","volume":"70","author":"JT Merrill","year":"2011","unstructured":"Merrill, J. T. et al. Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70, 1905\u20131913 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"35602_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.smim.2011.01.009","volume":"23","author":"L R\u00f6nnblom","year":"2011","unstructured":"R\u00f6nnblom, L., Alm, G. V. & Eloranta, M. L. The type I interferon system in the development of lupus. Semin. Immunol. 23, 113\u2013121 (2011).","journal-title":"Semin. Immunol."},{"key":"35602_CR55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2249.2009.03880.x","volume":"156","author":"KO Kong","year":"2009","unstructured":"Kong, K. O. et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin. Exp. Immunol. 156, 134\u2013140 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"35602_CR56","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","volume":"72","author":"T Rose","year":"2013","unstructured":"Rose, T. et al. IFN\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 72, 1639\u20131645 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"35602_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/107999099313901","volume":"19","author":"WJ Jabs","year":"1999","unstructured":"Jabs, W. J., Hennig, C., Zawatzky, R. & Kirchner, H. Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J. Interferon Cytokine Res. 19, 463\u2013469 (1999).","journal-title":"Interferon Cytokine Res."},{"key":"35602_CR58","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100, 2610\u20132615 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"35602_CR59","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0076-6879(09)05418-4","volume":"461","author":"GS Campanella","year":"2009","unstructured":"Campanella, G. S. & Luster, A. D. Chapter 18. A chemokine-mediated in vivo T-cell recruitment assay. Methods Enzymol. 461, 397\u2013412 (2009).","journal-title":"Methods Enzymol."},{"key":"35602_CR60","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Exp. Cell Res. 317, 620\u2013631 (2011).","journal-title":"Exp. Cell Res."},{"key":"35602_CR61","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.4049\/jimmunol.160.8.4074","volume":"160","author":"A Schwarting","year":"1998","unstructured":"Schwarting, A. et al. IFN-gamma limits macrophage expansion in MRL-Fas(lpr) autoimmune interstitial nephritis: a negative regulatory pathway. J. Immunol. 160, 4074\u20134081 (1998).","journal-title":"J. Immunol."},{"key":"35602_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1191\/0961203305lu2053oa","volume":"14","author":"M Aringer","year":"2005","unstructured":"Aringer, M. & Smolen, J. S. Cytokine expression in lupus kidneys. Lupus 14, 13\u201318 (2005).","journal-title":"Lupus"},{"key":"35602_CR63","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1681\/ASN.V85720","volume":"8","author":"C Zoja","year":"1997","unstructured":"Zoja, C. et al. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J. Am. Soc. Nephrol. 8, 720\u2013729 (1997).","journal-title":"J. Am. Soc. Nephrol."},{"key":"35602_CR64","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1681\/ASN.V1271369","volume":"12","author":"G P\u00e9rez de Lema","year":"2001","unstructured":"P\u00e9rez de Lema, G. et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol. 12, 1369\u20131382 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"35602_CR65","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/sj.gene.6364286","volume":"7","author":"J Liu","year":"2006","unstructured":"Liu, J. et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun. 7, 156\u2013168 (2006).","journal-title":"Genes Immun."},{"key":"35602_CR66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1523-1755.1999.00544.x","volume":"56","author":"S Segerer","year":"1999","unstructured":"Segerer, S., Mack, M., Regele, H., Kerjaschki, D. & Schl\u00f6ndorff, D. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int. 56, 52\u201364 (1999).","journal-title":"Kidney Int."},{"key":"35602_CR67","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.V11122231","volume":"11","author":"S Segerer","year":"2000","unstructured":"Segerer, S. et al. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J. Am. Soc. Nephrol. 11, 2231\u20132242 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"35602_CR68","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000013603","volume":"20","author":"K Furuichi","year":"2000","unstructured":"Furuichi, K. et al. Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases. Am. J. Nephrol. 20, 291\u2013299 (2000).","journal-title":"Am. J. Nephrol."},{"key":"35602_CR69","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1046\/j.1523-1755.2002.00480.x","volume":"62","author":"S Segerer","year":"2002","unstructured":"Segerer, S. et al. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int. 62, 488\u2013495 (2002).","journal-title":"Kidney Int."},{"key":"35602_CR70","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/art.24136","volume":"60","author":"P Enghard","year":"2009","unstructured":"Enghard, P. et al. CXCR3\u2009+\u2009CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum. 60, 199\u2013206 (2009).","journal-title":"Arthritis Rheum."},{"key":"35602_CR71","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3727\/096368915X689442","volume":"25","author":"EW Choi","year":"2016","unstructured":"Choi, E. W. et al. Comparative Efficacies of Long-Term Serial Transplantation of Syngeneic, Allogeneic, Xenogeneic, or CTLA4Ig-Overproducing Xenogeneic Adipose Tissue-Derived Mesenchymal Stem Cells on Murine Systemic Lupus Erythematosus. Cell Transplant. 25, 1193\u20131206 (2016).","journal-title":"Cell Transplant."},{"key":"35602_CR72","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/art.33313","volume":"64","author":"EW Choi","year":"2012","unstructured":"Choi, E. W. et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 64, 243\u2013253 (2012).","journal-title":"Arthritis Rheum."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35602-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T07:50:28Z","timestamp":1694073028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35602-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35602-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.H. and Y.I.C. are employed by Chong Kun Dang Pharmaceuticals, Inc. The other authors have no competing interests to declare. This study was supported by a research grant from Chong Kun Dang Pharmaceuticals, Inc. to E.W.C. and S.J.K.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17297"}}